Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Reports Widened Loss, Shrunken Revenue in Q4

NEW YORK, Jan. 31 - Nanogen on Thursday reported widened net losses in the fourth quarter 2001 atop fallen revenues.


Revenues for the period ended Dec. 31 fell to $2.3 million from $3.0 million one year ago as Nanogen's income was generated primarily from product revenues as opposed to sponsored research, the company said in a statement.


Net loss in the quarter was $7.5 million, or $.35  a share, compared with $5.9 million, or $.29 in the same period one year ago.


The San Diego-based company said it has $67.5 million in the bank.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.